natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered the increase in progression free survival to be clinically significant although it noted that a benefit in overall survival had not yet been shown.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je podaljšanje preživetja brez napredovanja bolezni klinično pomembno, čeprav korist pri skupnem preživetju še ni bila dokazana.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Abilify Maintena’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Abilify Maintena večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Adempas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Adempas večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Anoro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Anoro večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Aubagio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Aubagio večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Blincyto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Blincyto večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Bosulif’s benefits are greater than its risks in a sub-group of patients with an unmet medical need and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da so koristi zdravila Bosulif večje od z njim povezanih tveganj pri podskupini bolnikov, katerih zdravstvene potrebe večinoma niso izpolnjene, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Brimica Genuair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Brimica Genuair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Briviact’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Briviact večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cerdelga’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cerdelga večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cinqaero večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Clopidogrel/Acetylsalicylic acid Teva’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Klopidogrel/acetilsalicilna kislina Teva večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cometriq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cometriq večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Corbilta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Corbilta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cosentyx’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cosentyx večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cotellic’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cotellic večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cyramza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cyramza večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Deltyba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Deltyba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Descovy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Descovy večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duaklir Genuair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Duaklir Genuair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duavive’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Duavive večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duloxetine Lilly’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Duloxetine Lilly večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Dutrebis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Dutrebis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ebymect’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ebymect večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Edistride’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Edistride večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Entresto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Entresto večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Entyvio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Entyvio večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Enzepi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Enzepi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Erivedge’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Erivedge večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Evotaz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Evotaz večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Feraccru’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Feraccru večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Fexeric’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Fexeric večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Flixabi has been shown to have a comparable quality, safety and effectiveness to Remicade.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je zdravilo Flixabi po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Remicade.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Fluenz Tetra’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Fluenz Tetra večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Galafold’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Galafold večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Gardasil 9’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Gardasil 9 večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Gazyvaro’s benefits are greater than its risks and recommended that it be approved for use in the European Union (EU).
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Gazyvaro večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Genvoya’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Genvoya večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Granupas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Granupas večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Harvoni’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Harvoni večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hemangiol’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hemangiol večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hetlioz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hetlioz večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexacima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hexacima večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hexyon večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iblias’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Iblias večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iclusig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Iclusig večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ikervis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ikervis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Imbruvica’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Imbruvica večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Imnovid’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Imnovid večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Incruse’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Incruse večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Invokana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Invokana večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ionsys’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ionsys večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Izba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Izba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Jardiance’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Jardiance večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Jinarc’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Jinarc večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kadcyla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kadcyla večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kanuma’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kanuma večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kengrexal’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kengrexal večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ketoconazole HRA’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ketokonazol HRA večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Keytruda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Keytruda večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kolbam’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kolbam večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kovaltry večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kyprolis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kyprolis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Latuda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Latuda večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.